Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure

Diabetes Care

Volumn 30, Issue 3, 2007, Pages 722-724

  Hoppe, Uta C ^a   Freemantle, Nick ^b   Cleland, John G F ^c   Marijianowski, Monique ^d   Erdmann, Erland ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d MEDTRONIC BAKKEN RESEARCH CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC DIET; DIABETIC PATIENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIAC PACING, ARTIFICIAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33847669374     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2035     Document Type: Article

References (29)

1. Solang L, Malmberg K, Ryden L: Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J 20:789-795, 1999
2. Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, de Groote P: Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2:1, 2003
3. Bell DS: Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26:2433-2441, 2003
4. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
5. Cleland JG, Clark AL: Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth. J Am Coll Cardiol 42:1234-1237, 2003
6. Khand A, Gemmel I, Clark AL, Cleland JG: Is the prognosis of heart failure improving? J Am Coll Cardiol 36:2284-2286, 2000
7. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC: Diabetes mellitus: a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77:1017-1020, 1996
8. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, Torp-Pedersen C: Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43:771-777, 2004
9. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB: Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27:65-75, 2006
10. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ: Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38:421-428, 2001
11. de Groote P, Lamblin N, Mouquet F, Plichon D, Mc Fadden E, Van Belle E, Bauters C: Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25:656-662, 2004
12. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR: The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42:914-922, 2003
13. Smooke S, Horwich TB, Fonarow GC: Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:168-174, 2005
14. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-1549, 2005
15. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM: Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140-2150, 2004
16. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J: Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002
17. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K, the Multicenter InSync ICD Randomized Clinical Evaluation (Miracle ICD) Trial Investigators: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289:2685-2694, 2003
18. Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT: Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation 108:266-269, 2003
19. Sinha AM, Filzmaier K, Breithardt OA, Kunz D, Graf J, Markus KU, Hanrath P, Stellbrink C: Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 91:755-758, 2003
20. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L, the CARE-HF Study Steering Committee and Investigators: The CARE-HF study (Cardiac Resynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 3:481-489, 2001
21. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L: Baseline characteristics of patients recruited into the CARE-HF. Eur J Heart Fail 7:205-214, 2005
22. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L: Longer-term effects of cardiac resynchronization therapy on mortality in heart failure: the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase). Eur Heart J 27:1928-1932, 2006
23. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E: Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114:18-25, 2006
24. Zakeri R, Freemantle N, Barnett V, Lipkin GW, Bonser RS, Graham TR, Rooney SJ, Wilson IC, Cramb R, Keogh BE, Pagano D: Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 112 (Suppl. I):270I-275I, 2005
25. Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: results from the ATLAS trial. Eur Heart J 21:1967-1978, 2000
26. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI: Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361:1843-1848, 2003
27. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003
28. Erdmann E, Lechat P, Verkenne P, Wiemann H: Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3:469-479, 2001
29. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J: Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149:159-167, 2005